Eddie Hickman
Stock Analyst at Guggenheim
(4.67)
# 813
Out of 4,974 analysts
47
Total ratings
69.6%
Success rate
35.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Reiterated: Buy | $69 → $100 | $12.89 | +675.80% | 8 | Aug 14, 2026 | |
| GHRS GH Research | Reiterated: Buy | $34 → $40 | $27.55 | +45.19% | 5 | Aug 6, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $24 → $23 | $11.65 | +97.42% | 9 | Aug 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 → $89 | $78.23 | +13.77% | 16 | Jul 21, 2026 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.673 | n/a | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $36.65 | n/a | 2 | Aug 11, 2025 |
ProMIS Neurosciences
Aug 14, 2026
Reiterated: Buy
Price Target: $69 → $100
Current: $12.89
Upside: +675.80%
GH Research
Aug 6, 2026
Reiterated: Buy
Price Target: $34 → $40
Current: $27.55
Upside: +45.19%
Zevra Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $24 → $23
Current: $11.65
Upside: +97.42%
Tarsus Pharmaceuticals
Jul 21, 2026
Reiterated: Buy
Price Target: $90 → $89
Current: $78.23
Upside: +13.77%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.673
Upside: n/a
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $36.65
Upside: n/a